Diadema Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Diadema Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$985K	–	160
2025 Q3	$985K	Buy	+50,000	New	+$1.03M	0.25%	88

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Diadema Partners's CPRX Position: Q4 2025 in Review

Diadema Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 50,000 shares — an estimated $985K sold.

Diadema Partners first reported a position in CPRX in Q3 2025 and held it in 1 quarter. The position peaked at $985K in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

Diadema Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 50,000 Catalyst Pharmaceutical shares in Q4 2025, an estimated $985K.
Diadema Partners first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 1 quarter.
Diadema Partners's Catalyst Pharmaceutical position peaked at $985K in Q3 2025.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.